However, patients with steatosis had more chronic liver disease (40% vs 23%, p=0.02) and higher baseline ALT levels (28 IU/L vs 17 IU/L, p=0.002), but not more cirrhosis (12.8% vs 15.6%, p=0.63). The median LOS in those with steatosis was 6.1 days (4-16), while 9 days (...
Some patients with NAFLD progress to non-alcoholic steatohepatitis, cirrhosis2, end-stage liver disease, and hepatocellular carcinoma3. There are currently no approved effective medications for the treatment of NAFLD, and the effectiveness of non-pharmacological treatments in this patient population is ...
Its progressive form, termed nonalcoholic steatohepatitis (NASH) (1), is a significant predisposing factor for the development of cryptogenic cirrhosis and hepatic failure and an increasingly common indication for liver transplantation (2, 3). Insulin resistance is a very significant contributor to the...
The pathological spectrum of NAFLD includes nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH), according to the severity of disease, NASH includes fibrosis, cirrhosis and hepatocellular carcinoma (HCC) [3]. At present, there are no approved therapies for NAFLD, novel ...
NAFLD is usually divided into non-progressive NAFLD-non-alcoholic fatty liver (NAFL) and progressive NAFLD-non-alcoholic steatohepatitis (NASH) (Singh et al., 2015), with patients suffering from the latter developing further liver damage and cirrhosis or liver cancer (Dulai et al., 2017, You...
NASH, a severe form of NAFLD that is accompanied by inflammation and fibrosis, progresses to cirrhosis and hepatic failure5. Thus, various pathological changes in genes and proteins, including those that produce metabolites, contribute to the progression of NAFLD. 1Department of Anatomy and ...
NAFLD is one of the most common causes of chronic liver disease in the Western world. It represents a spectrum of conditions ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), where steatosis is associated with hepatic inflammation and various degrees of fibrosis and cirrhosis, whi...
NAFLD is one of the most common causes of chronic liver disease in the Western world. It represents a spectrum of conditions ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), where steatosis is associated with hepatic inflammation and various degrees of fibrosis and cirrhosis, whi...
Nonalcoholic fatty liver disease (NAFLD) is associated with obesity and insulin resistance12,13, and often leads to steatohepatitis, liver fibrosis and cirrhosis14. It has been reported that PPARc signaling is involved in the pathogenesis of hepatic steatosis15,16. PPARc and its targeted genes ...
Twelve to 20% of NAFLD patients develop an inflammatory response and nonalcoholic steatohepatitis, and 5 to 15% progress to fibrosis and cirrhosis as the final stage of the disease, which is a great risk factor for hepatocellular carcinoma (2–4). Ten percent of liver transplants in the USA...